Mission Statement, Vision, & Core Values (2024) of Calithera Biosciences, Inc. (CALA)

Mission Statement, Vision, & Core Values (2024) of Calithera Biosciences, Inc. (CALA)

US | Healthcare | Biotechnology | NASDAQ

Calithera Biosciences, Inc. (CALA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Calithera Biosciences, Inc. (CALA)

General Summary of Calithera Biosciences, Inc. (CALA)

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs for cancer and other metabolic diseases.

Company Detail Specific Information
Headquarters South San Francisco, California
Founded 2010
Stock Exchange NASDAQ: CALA

Key Product Portfolio

  • Glutaminase inhibitor program
  • Arginase inhibitor program
  • Preclinical oncology therapeutics

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $12.4 million
Net Loss ($48.3 million)
Cash and Investments $84.6 million

Industry Leadership Position

Calithera Biosciences specializes in developing innovative metabolic therapies targeting cancer metabolism. The company's research focuses on unique metabolic pathways that could potentially disrupt cancer cell growth.

Research Focus Current Stage
Glutaminase Inhibitor (CB-839) Clinical Stage
Arginase Inhibitor (INCB001158) Clinical Development



Mission Statement of Calithera Biosciences, Inc. (CALA)

Mission Statement of Calithera Biosciences, Inc. (CALA)

Calithera Biosciences, Inc. focuses on developing innovative therapies targeting tumor metabolism and tumor microenvironment to treat cancer and other serious diseases.

Core Components of Mission Statement

Component Specific Focus Research Target
Therapeutic Innovation Metabolic Targeting Cancer Treatment
Research Strategy Tumor Microenvironment Precision Medicine

Research and Development Metrics

Key financial and research metrics for Calithera Biosciences:

  • Research and Development Expenses: $37.4 million (2022)
  • Clinical Pipeline: 2 primary investigational drug candidates
  • Market Capitalization: Approximately $11.5 million (January 2024)

Therapeutic Focus Areas

Disease Category Specific Research Target Development Stage
Oncology Glutaminase Inhibition Clinical Trial Phase
Metabolic Disorders Enzyme Targeting Preclinical Research

Strategic Research Approach

Key Research Platforms:

  • Glutaminase Inhibition (CB-839)
  • Arginase Inhibition (INCB001158)
  • Tumor Microenvironment Modulation

Financial Performance Indicators

Financial data for Calithera Biosciences:

  • Net Loss: $46.3 million (2022)
  • Cash and Cash Equivalents: $32.7 million (Q3 2023)
  • Operating Expenses: $41.2 million (2022)



Vision Statement of Calithera Biosciences, Inc. (CALA)

Vision Statement of Calithera Biosciences, Inc. (CALA)

Therapeutic Focus and Strategic Direction

Calithera Biosciences, Inc. aims to develop innovative therapies targeting tumor metabolism and tumor microenvironment to address unmet medical needs in oncology.

Key Vision Components Specific Details
Research Priority Metabolic targeting in cancer therapeutics
Primary Research Areas Tumor metabolism, immuno-oncology
Clinical Stage Programs Phase 1/2 clinical trials
Research and Development Strategy
  • Develop novel small molecule therapeutics
  • Target metabolic pathways in cancer cells
  • Enhance immune system response in oncology treatments

As of 2024, Calithera maintains a focused approach on developing precision medicine solutions in oncology, with specific emphasis on metabolic interventions.

Therapeutic Pipeline Overview
Program Current Status Target Indication
INCB001158 Clinical Development Solid Tumors
CB-280 Preclinical Stage Metabolic Targeting
Technological Innovation Approach

Calithera focuses on developing proprietary technologies that disrupt cancer metabolism and enhance therapeutic interventions.

  • Precision targeting of metabolic vulnerabilities
  • Innovative small molecule design
  • Immuno-oncology platform development



Core Values of Calithera Biosciences, Inc. (CALA)

Core Values of Calithera Biosciences, Inc. (CALA) in 2024

Innovation and Scientific Excellence

Calithera Biosciences demonstrates commitment to innovation through its research and development efforts in oncology and metabolism-focused therapeutics.

R&D Investment Amount (2023)
Total Research Expenses $43.7 million
New Drug Development 3 active clinical programs

Patient-Centric Approach

Calithera focuses on developing treatments for challenging medical conditions.

  • Oncology therapeutic focus
  • Metabolism-related disease research
  • Precision medicine development

Scientific Collaboration and Transparency

Collaboration Type Number of Partnerships
Academic Research Partnerships 4
Pharmaceutical Collaborations 2

Ethical Research Practices

Calithera maintains rigorous ethical standards in clinical research and development.

  • FDA compliance protocols
  • Institutional Review Board (IRB) oversight
  • Transparent clinical trial reporting

Financial Commitment to Research

Financial Metric 2023 Value
Cash and Cash Equivalents $85.4 million
Net Loss $56.2 million

DCF model

Calithera Biosciences, Inc. (CALA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.